首页> 美国卫生研究院文献>Molecular Pharmacology >Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity Affinity and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships
【2h】

Investigating Metabotropic Glutamate Receptor 5 Allosteric Modulator Cooperativity Affinity and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships

机译:研究代谢型谷氨酸受体5变构调节剂的协同性亲和力和激动性:丰富的结构功能研究和结构活性关系。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug discovery programs increasingly are focusing on allosteric modulators as a means to modify the activity of G protein-coupled receptor (GPCR) targets. Allosteric binding sites are topographically distinct from the endogenous ligand (orthosteric) binding site, which allows for co-occupation of a single receptor with the endogenous ligand and an allosteric modulator that can alter receptor pharmacological characteristics. Negative allosteric modulators (NAMs) inhibit and positive allosteric modulators (PAMs) enhance the affinity and/or efficacy of orthosteric agonists. Established approaches for estimation of affinity and efficacy values for orthosteric ligands are not appropriate for allosteric modulators, and this presents challenges for fully understanding the actions of novel modulators of GPCRs. Metabotropic glutamate receptor 5 (mGlu5) is a family C GPCR for which a large array of allosteric modulators have been identified. We took advantage of the many tools for probing allosteric sites on mGlu5 to validate an operational model of allosterism that allows quantitative estimation of modulator affinity and cooperativity values. Affinity estimates derived from functional assays fit well with affinities measured in radioligand binding experiments for both PAMs and NAMs with diverse chemical scaffolds and varying degrees of cooperativity. We observed modulation bias for PAMs when we compared mGlu5-mediated Ca2+ mobilization and extracellular signal-regulated kinase 1/2 phosphorylation data. Furthermore, we used this model to quantify the effects of mutations that reduce binding or potentiation by PAMs. This model can be applied to PAM and NAM potency curves in combination with maximal fold-shift data to derive reliable estimates of modulator affinities.
机译:药物发现计划越来越多地将变构调节剂作为修饰G蛋白偶联受体(GPCR)靶标活性的手段。变构结合位点在外形上与内源配体(正构)结合位点不同,这允许单个受体与内源配体和可改变受体药理学特征的变构调节剂共同占据。负变构调节剂(NAM)抑制,正变构调节剂(PAM)增强正构激动剂的亲和力和/或功效。建立的估计正构配体亲和力和功效值的方法不适用于变构调节剂,这为充分理解GPCR的新型调节剂的作用提出了挑战。代谢型谷氨酸受体5(mGlu5)是C系列CPCR,已鉴定出大量的变构调节剂。我们利用了许多工具来探测mGlu5上的变构位点,以验证变构作用的操作模型,该模型可以定量估计调节剂的亲和力和协同作用值。从功能分析得出的亲和力估算值与在放射性配体结合实验中针对具有各种化学支架和不同程度的协同作用的PAM和NAM所测量的亲和力非常吻合。当比较mGlu5介导的Ca 2 + 动员和细胞外信号调节激酶1/2磷酸化数据时,我们观察到PAMs的调制偏倚。此外,我们使用此模型来量化减少PAM结合或增强作用的突变的影响。该模型可以结合最大倍数移位数据应用于PAM和NAM效能曲线,以得出调制器亲和力的可靠估计值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号